» Articles » PMID: 35330864

The Role of MicroRNA in the Pathogenesis of Glial Brain Tumors

Overview
Date 2022 Mar 25
PMID 35330864
Authors
Affiliations
Soon will be listed here.
Abstract

Gliomas are the most common and fatal primary brain tumor in adults. Gliomas are highly invasive tumors with the highest mortality among all primary malignant brain tumors. Until now, the molecular mechanism that is responsible for glioma tumorigenesis and progression remains unclear. MicroRNAs (miRNAs) are short non-coding RNAs with 18-22 nucleotides in length which function as key regulators of various biological processes through negative control over gene expression at the post-transcriptional level. MiRNA dysregulation plays a key role in cancer oncogenesis, including the development and progression of gliomas. MiRNAs regulate a wide range of tumor processes including cell proliferation, differentiation, angiogenesis, invasion and apoptosis. In addition, microRNAs can be selectively packaged, secreted, and transported between cells in exosomes that are able to cross the blood-brain barrier (BBB) and are readily available in almost all types of human body fluids, making them promising biomarkers for gliomas. Increasing evidence has shown that miRNAs play an important role in glioma. For example, a large number studies indicated that this miRNA-21could affect on a variety of cellular and molecular pathways such as insulin-like growth factor (IGF)-binding protein-3 (IGFBP3), RECK, and TIMP3. Exosomal miR-21 may has key roles in gliomas pathogenesis. These findings indicated that miR-21 has critical roles in gliomas pathogenesis and could be used as diagnostic and therapeutic biomarkers for glioma patients. Profiling miRNAs expression in various human pathological conditions is a rapidly growing field, and it is likely that the knowledge gained from these studies regarding the genesis of gliomas will have the potential in the field of minimally invasive therapy with miRNA to improve the prognosis of patients with this pathology.

Citing Articles

Natural compounds as regulators of miRNAs: exploring a new avenue for treating brain cancer.

Doghish A, El-Dakroury W, Abulsoud A, Abdelmaksoud N, Aly S, Elbadry A Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40047858 DOI: 10.1007/s00210-025-03934-1.


Tight junction proteins in glial tumors development and progression.

Moskal J, Michalak S Front Cell Neurosci. 2025; 19:1541885.

PMID: 39963115 PMC: 11830821. DOI: 10.3389/fncel.2025.1541885.


Subependymal Giant Cell Astrocytoma: The Molecular Landscape and Treatment Advances.

Pucko E, Sulejczak D, Ostrowski R Cancers (Basel). 2024; 16(19).

PMID: 39410026 PMC: 11475231. DOI: 10.3390/cancers16193406.


Overexpression of hsa_circ_0061817 Can Inhibit the Proliferation and Invasion of Lung Cancer Cells Based on Active Compounds.

Ye L, Zhong Y, Hu L, Huang Y, Tang X, Yu S Oxid Med Cell Longev. 2024; 2022:4509019.

PMID: 39282154 PMC: 11401659. DOI: 10.1155/2022/4509019.


The potential of miRNA-based approaches in glioblastoma: An update in current advances and future perspectives.

Ordonez-Rubiano E, Rincon-Arias N, Espinosa S, Shelton W, Salazar A, Combita A Curr Res Pharmacol Drug Discov. 2024; 7:100193.

PMID: 39055532 PMC: 11268206. DOI: 10.1016/j.crphar.2024.100193.


References
1.
Buckner J, Shaw E, Pugh S, Chakravarti A, Gilbert M, Barger G . Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med. 2016; 374(14):1344-55. PMC: 5170873. DOI: 10.1056/NEJMoa1500925. View

2.
Pang C, Guan Y, Zhao K, Chen L, Bao Y, Cui R . Up-regulation of microRNA-15b correlates with unfavorable prognosis and malignant progression of human glioma. Int J Clin Exp Pathol. 2015; 8(5):4943-52. PMC: 4503059. View

3.
Chang J, Hwang Y, Lee D, Kim D, Park J, Wu H . MicroRNA-203 Modulates the Radiation Sensitivity of Human Malignant Glioma Cells. Int J Radiat Oncol Biol Phys. 2015; 94(2):412-20. DOI: 10.1016/j.ijrobp.2015.10.001. View

4.
Areeb Z, Stylli S, Koldej R, Ritchie D, Siegal T, Morokoff A . MicroRNA as potential biomarkers in Glioblastoma. J Neurooncol. 2015; 125(2):237-48. DOI: 10.1007/s11060-015-1912-0. View

5.
Gao Y, Chen X, Liu H . Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression. Sci Rep. 2016; 6:32972. PMC: 5011744. DOI: 10.1038/srep32972. View